[Federal Register Volume 69, Number 105 (Tuesday, June 1, 2004)]
[Notices]
[Pages 30917-30918]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 04-12225]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30Day-54-04]


Proposed Data Collections Submitted for Public Comment and 
Recommendations

    The Centers for Disease Control and Prevention (CDC) publishes a 
list of information collection requests under review by the Office of 
Management and Budget (OMB) in compliance with the Paperwork Reduction 
Act (44 U.S.C. Chapter 35). To request a copy of these requests, call 
the CDC Reports Clearance Officer at (404) 498-1210 or send an e-mail 
to [email protected]. Send written comments to CDC, Desk Officer, Human 
Resources and Housing Branch, New Executive Office Building, Room 
10235, Washington, DC 20503 or by fax to (202) 395-6974. Written 
comments should be received within 30 days of this notice.

Proposed Project

    Evaluation of Educational Materials Promoting Informed Decision-
Making About Prostate Cancer Screening--New--National Center for 
Chronic Disease Prevention and Health Promotion (NCCDPHP), Centers for 
Disease Control and Prevention (CDC).
    Prostate cancer is the second most commonly diagnosed cancer among 
men in the United States. In 2003, an estimated 220,900 new cases of 
prostate cancer was diagnosed, and approximately 28,900 men died from 
the disease. The effectiveness of prostate cancer screening has not 
been established. A number of clinical guidelines recommend that the 
potential

[[Page 30918]]

risks and benefits of prostate cancer screening be explained to 
patients so that they may make an informed decision about screening. 
The purpose of this project is to evaluate the effectiveness of an 
informed-decision making booklet about prostate cancer screening 
developed by CDC.
    This is a 3-year project that will be conducted in two phases of 
which 3 major tasks must be completed. In Task-1, the reliability and 
validity of a measurement instrument assessing prostate cancer 
knowledge and related variables will be tested. Two hundred men of all 
races aged 50 to 70 years and 200 African-American men aged 40 to 70 
years will read the CDC booklet and complete the measurement 
instrument. In Task-2, 150 primary care physicians will complete a 
survey measuring their prostate cancer screening practices. The survey 
will be administered once and then again several months later. In Task-
3, 400 men aged 50-70 years will take part in a randomized controlled 
trial. Men in the intervention group will be asked to read the CDC 
booklet and complete the measurement instrument tested in Task-1, and 
men in the control group will complete the measurement instrument 
without reading the CDC booklet. There is no cost to respondent except 
for their time.

----------------------------------------------------------------------------------------------------------------
                                                                     Number of      Avg. burden
                    Form name                        Number of     responses per   per response    Total burden
                                                    respondents     respondent       (in hrs.)       (in hrs.)
----------------------------------------------------------------------------------------------------------------
                                  Phase I: Replicate Measures Validation Study
----------------------------------------------------------------------------------------------------------------
Eligibility Screener............................             147               1           15/60              37
Pre-visit Instrument 1..........................             133               1        \1\15/60              33
Pre-visit Instrument 2..........................             133               1       \2\ 30/60              67
After visit Instrument..........................             133               1           20/60              44
-------------------------------------------------
                                      Phase II: Randomized Controlled Trial
----------------------------------------------------------------------------------------------------------------
Eligibility Screener............................             160               1           15/60              40
Pre-visit Instrument 1..........................             133               1           15/60              33
Pre-visit Instrument 2..........................              67               1           30/60              34
After visit Instrument..........................             133               1           30/60              67
Provider Practice Screener 1 (Pre-RCT)..........              50               1           15/60              13
Provider Practice Screener 2 (Pre-RCT)..........              50               1           15/60              13
                                                 -----------------
    Total.......................................  ..............  ..............  ..............            381
----------------------------------------------------------------------------------------------------------------
\1\ Includes preparation and returning the survey via mail service.
\2\ Includes an estimate of 25 minutes for reviewing the decision aid material.


    Dated: May 20, 2004.
Joe E. Salter,
Acting Director, Management Analysis and Services Office, Centers for 
Disease Control and Prevention.
[FR Doc. 04-12225 Filed 5-28-04; 8:45 am]
BILLING CODE 4163-18-P